January 23-25, 2018

San Francisco, CA


Day One
Wednesday January 24th, 2017

Day Two
Thursday, January 25th 2018


Chairperson’s Opening Remarks

Transforming Translational Research: CANscript™ – A Better Predictive Model For Oncology

  • Mark Paris Associate Director, Translational Applications Biopharma Business Development, Mitra Biotech Inc.


  • Mitra Biotech has developed and clinically validated fully human ex-vivo platform technology (CANscript™)
  •  CANscript ™ uses patient material (tumor, autologous ligands and immune cells) to explore the mechanism of and predict efficacy for clinically-directed compounds across several drug classes
  •  This talk will explore how CANscript can better enable your translational efforts and aid in advancing your highest potential candidate into successful clinical trials

Characterization of ADME Properties of Novel Protein Therapeutics


  • Next generation protein therapeutics are engineered in an attempt to improve the efficacy of monoclonal antibody therapeutics in the oncology setting.
  • Designing multifunctional therapeutics for enhanced pharmacologic activity or improved target selectivity.
  • Altering the targeting and/or activity of a molecule can concomitantly lead to novel and unanticipated ADME properties and pharmacokinetics for the therapeutic.
  • Characterization of the stability and overall disposition of bispecific antibodies and antibody-cytokine fusion proteins to help guide engineering and selection of lead candidates.

Morning Refreshments

Novel Bone Metastasis Models in Syngeneic and Humanized Mice


  • Importance of tumor microenvironment
  • Testing antitumor efficacy in bone metastasis models
  • Immunotherapy and bone

Strategies for Using Models In CAR T Cell Research and Development

  • Rafael Ponce Sr. Director, Preclinical Sciences, Juno Therapeutics


  • Optimizing your preclinical models for CAR T cell research and development
  • Challenges involved when characterizing your preclinical models for Car T cell research

Utilization of Murine Breast Cancer Models in Preclinical Immuno-Oncology Pharmacology

  • Dylan Daniel Director - Scientific Development, MI Bioresearch


  • Pros and Cons of the 4T1 Mammary Cancer Model
  • Characteristics of Alternative Syngeneic Breast Models
  • Responses of a New Model to Checkpoint Inhibition and T Cell Costimulation

Optimizing Preclinical Models for The Development of T Cell Dependent Bispecific (TDBs) Antibody Therapies Targeting Solid Tumors


  • Overview of TDB antibodies
  • Limitations of using syngeneic and GEMM in vivo models to demonstrate antitumor
    efficacy of TDBs in solid tumors
  • Utilizing the huPBMC transfer model in NSG mice to demonstrate efficacy and
    establish preclinical therapeutic index of TDB antibodies

Lunch and Networking

Multiplexing CAR T Cell Therapy


  • Bispecific CARs targeting 2 antigens in ALL
  • Multiplexing CAR with regulatory CARs
  • How to track multiple CARs In Vitro and In Vivo

Evaluating Preclinical Predictions for the Development of Combinations with Targeted Therapies & Immunotherapies

  • Andrew Rhim CPRIT Scholar in Cancer Research, Associate Director for Translational Research , in Pancreatic Cancer Research, MD Anderson Cancer Center


  • Describing models used and key considerations for experimental design
  • Model responses and predictability of combination efficacy

Chairperson’s Closing Remarks


Close of the Annual Tumor Models San Francisco Summit